- Opill® and Collier will hit the road to talk to
women about their reproductive health options.
GRAND
RAPIDS, Mich., Oct. 15,
2024 /PRNewswire/ -- Today, Opill®—the
first and only daily birth control pill available without a
prescription in the U.S.—announces the launch of its partnership
with WNBA Star and two-time Olympic Gold Medalist Napheesa
Collier. The collaboration builds on Opill's multi-year partnership
with the Women's National Basketball Association (WNBA).
"One of the reasons Opill partnered with the WNBA
is because the players are so passionate about using their platform
to champion causes they believe in," said Leila Bahbah, Perrigo U.S. Women's Health Brand
Lead. "Napheesa exudes that passion, and together we plan to
educate and empower people to take charge of their reproductive
health".
Collier - an Olympic Gold Medalist, starting
forward for the Minnesota Lynx, and a mother - is an advocate for
women, and says that she's ready for the conversations, even if
they're difficult.
"It is important, especially now, to talk
to women about their options when it comes to reproductive health,"
said Collier. "I am ready to get out there and have these very
important conversations, and to help women learn about accessing
the birth control that's right for them, including Opill."
Collier was most recently named the Kia 2024 WNBA
Defensive Player of the Year and finished second in MVP voting. Her
resume also includes the 2019 Kia WNBA Rookie of the Year award,
and four AT&T WNBA All-Star selections in addition to those two
Olympic gold medals as part of Team USA. She says, however, that her greatest
achievement is becoming a mother, and that one reason she was eager
to partner with Opill was to make the world better for her
daughter, Mila.
"I don't take for granted the opportunity to be
part of positive change now that will continue to impact the next
generation. I am proud to play a part in helping women get access
to birth control if they want it."
As part of the partnership, Collier will hit the
road with Opill® in support of the brand's efforts to
reach students on college campuses nationwide. These educational
events will aim to increase awareness about the availability of
Opill® and educate students on reproductive health and
the importance of safe, effective and affordable contraception in
the U.S.
Opill®, developed by Perrigo, is the
first daily birth control pill available without a prescription in
the U.S. This landmark development represents a significant step
forward in women's healthcare, providing a convenient and
accessible option for contraception. With Opill®, women
no longer need to visit a healthcare provider for a prescription,
making it easier than ever to take control of their reproductive
health.
To learn more about Opill®, visit
Opill.com or follow @opill_OTC on Instagram,
TikTok, Facebook, Threads and X.
About Opill®
Opill® is the first ever and only
over-the-counter birth control pill available in the United States. It is a progestin-only
daily oral contraceptive that's safe and effective when used as
directed to help prevent pregnancy. Do not use Opill® if
you have or ever had breast cancer. See Opill® Drug
Facts label for list of warnings. Opill® is not an
emergency contraceptive (morning after pill) and won't prevent
pregnancy when used after unprotected sex. It also doesn't protect
against HIV/AIDS or other sexually transmitted diseases (STDs). For
more information, please visit www.opill.com or
follow @opill_OTC on Instagram, TikTok, Facebook, Threads
and X.
About Perrigo
Perrigo Company plc (NYSE: PRGO), is a leading
provider of Consumer Self-Care Products and
over-the-counter (OTC) health and wellness solutions that enhance
individual well-being by empowering consumers to proactively
prevent or treat conditions that can be self-managed. Visit Perrigo
online at www.perrigo.com.
Contact
Media:
All Opill®-related media inquiries to be directed to:
press@opill.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/wnba-star-napheesa-collier-joins-team-opill-for-candid-conversations-on-womens-health-302275871.html
SOURCE Perrigo Company plc